NCT00385255View on ClinicalTrials.gov

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,726

Participants

Timeline

Start Date

October 23, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Acellular PertussisDiphtheriaTetanus
Interventions
BIOLOGICAL

Fluarix®

GSK Biologicals' inactivated influenza split virus vaccine.

BIOLOGICAL

Boostrix®

GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

Trial Locations (12)

15217

GSK Investigational Site, Pittsburgh

15220

GSK Investigational Site, Pittsburgh

32935

GSK Investigational Site, Melbourne

33024

GSK Investigational Site, Pembroke Pines

34452

GSK Investigational Site, Inverness

35802

GSK Investigational Site, Huntsville

37620

GSK Investigational Site, Bristol

61602

GSK Investigational Site, Peoria

77024

GSK Investigational Site, Houston

85014

GSK Investigational Site, Phoenix

85213

GSK Investigational Site, Mesa

85224

GSK Investigational Site, Chandler

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY